Kyverna Therapeutics (KYTX) Total Current Liabilities (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Total Current Liabilities came in at $29.7 million in Q1 2026, down 10.87% YoY from $33.3 million in Q1 2025, and down 18.67% on a QoQ basis from $36.5 million in Q4 2025.
Kyverna Therapeutics (KYTX) Total Current Liabilities (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Total Current Liabilities data on file, last reported at $29.7 million in Q1 2026.
- Quarterly Total Current Liabilities fell 10.87% year-over-year to $29.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.7 million (down 10.87% YoY) and the FY2025 annual result came in at $36.5 million, up 8.09% from the prior year.
- Total Current Liabilities retreated to $29.7 million in Q1 2026, from $36.5 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $39.8 million in Q2 2025 to a low of $19.9 million in Q4 2023.
- A 4-year average of $30.3 million and a median of $32.1 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities soared 69.98% — and 2026, when it fell 10.87%.
- Tracing KYTX's Total Current Liabilities over 4 years: stood at $19.9 million in 2023, then soared by 69.98% to $33.8 million in 2024, then increased by 8.09% to $36.5 million in 2025, then retreated by 18.67% to $29.7 million in 2026.
- The last three Total Current Liabilities figures came in at $29.7 million (Q1 2026), $36.5 million (Q4 2025), and $33.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | 22.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.80 Mn |
| Mar 31, 2026 | 29.67 Mn |
| Dec 31, 2025 | 36.49 Mn |
| Sep 30, 2025 | 33.87 Mn |
| Jun 30, 2025 | 39.79 Mn |
| Mar 31, 2025 | 33.29 Mn |
| Dec 31, 2024 | 33.76 Mn |
| Sep 30, 2024 | 30.99 Mn |
| Jun 30, 2024 | 23.48 Mn |
| Mar 31, 2024 | 21.87 Mn |
| Dec 31, 2023 | 19.86 Mn |